Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia: Editorial comment

Journal of Urology

Volumn 174, Issue 6, 2005, Pages 2275-2276

  O'Leary, Michael P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DARIFENACIN; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; TOLTERODINE;

BLADDER CAPACITY; BLADDER COMPLIANCE; CLINICAL ARTICLE; CLINICAL TRIAL; DETRUSOR DYSSYNERGIA; DRUG CONTRAINDICATION; DRUG EFFICACY; HUMAN; LOWER URINARY TRACT SYMPTOM; MALE; MICTURITION DISORDER; NOTE; PILOT STUDY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SCORING SYSTEM; SYMPTOM; TREATMENT FAILURE; URINARY TRACT DISEASE; URINE FLOW RATE; URINE RETENTION;

EID: 27744560465     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (2)

1. McGuire, E. J.: Neuromuscular dysfunction of the lower urinary tract. In: Campbell's Urology. Edited by P. C. Walsh, R. Gittes, A. Perlmutter and T. Stamey. Philadelphia: W. B. Saunders, p. 633, 1986
2. Chapple, C. R.: Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practicing clinician. BJU Int, 94: 738, 2004